App-Quantinova.ai

Living with Leukaemia; identifying specific issues facing leukaemia patients in the UK

Z. Pemberton-Whiteley - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic Lymphocytic Leukemia

N/A

Age‐Related Clonal Haematopoiesis in a Ugandan Cohort and its Contribution to Anaemia: A Pilot Study

C. Hayden - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

The diagnostic value of Neutrophil Gelatinase –Associated Lipocalin (NGAL) for detecting early phase sepsis in patients with suspected bacterial infection

N. Mutenta - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Neutropenia

N/A

Prescribing Practice and Clinical Outcomes in a real‐world Chronic Myeloid Leukaemia Regional Cohort

U. Reddy - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Nilotinib

Normocytic anaemia is more common than microcytic anaemia in Gastro‐intestinal (GI) cancers: A large single centre study

F. Lourenco - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Autoimmune haemolytic anaemia: A survey of diagnostic and management practice in England

M. Horan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Autoimmune hemolytic anemia

Prednisolone

Regional experience of screening for JAK2 exon 12 mutations, independent of erythropoietin level stratification, during the investigation of JAK2 V617F negative erythrocytosis

K.R. Lindsay - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Polycythaemia vera

Erythropoietin

Oral prednisolone therapy switches pro‐inflammatory intermediate monocytes in treatment‐naïve immune thrombocytopenia patients to an anti‐inflammatory phenotype

E. Williams - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Glucocorticoid

Mutational profiling in triple‐negative essential thrombocythaemia with targeted next‐generation sequencing

O. Michail - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myeloid neoplasms

EZH2

EastKentSKI: Successful TKI discontinuation ‐ characteristics of nine patients who successfully stopped TKIs in chronic phase CML

C. Grist - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

dasatinib

Awareness of interactions caused by complementary medicine and food among patients with CML

D. Sparksman - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Re‐evaluation and collaboration of laboratory testing pathway for iron deficiency anaemia

N. Svenson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Single Centre Immune Thrombocytopaenia Therapy Response Analysis

P. Woolley - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Eltrombopag

Ferroportin Disease: One Hospital's Experience in Diagnosis and Management

G. Talbot - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Anemia

N/A

“Just send it for flow”: trends, diagnostic yield and cost of immunophenotyping for cerebrospinal fluid

R. Dunk - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Administration of intravenous iron to optimise haemoglobin pre‐operatively

R. Newton - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anemia

Ferric carboxymaltose

The role of percentage hypochromic red cells as a screening tool for iron deficiency anaemia in pre‐operative anaemic patients with normal renal function

R. Andrews - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Anemia

Cyanocobalamin

A rare neurological presentation of myeloid neoplasm with eosiniphilia and rearrangement of PDGFRA

D. Sharpe - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

PDGFRA rearrangement

Hydroxycarbamide

Bone Marrow Biopsy‐ Lessons from a single centre

E. Ladikou - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Warfarin

A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK

C. Harrison - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

N/A

Filters

45280 Abstracts